Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orchid PharmaLUX:ORCHP 60 Debt-to-EBITDA is 2.61 as of Mar. 2026, which is 45% below its 10-year median of 4.76. GuruFocus rates LUX:ORCHP with a GF Score™ of 60/100 and a GF Value™ of $4.67. The stock has 10 warning signs investors should review. Among 691 Drug Manufacturers companies, Orchid Pharma ranks worse than 81.48% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Orchid Pharma's Debt-to-EBITDA or its related term are showing as below:
LUX:ORCHP'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -46.74 Med: 4.76 Max: 88.95
Current: 5.2
During the past 13 years, the highest Debt-to-EBITDA Ratio of Orchid Pharma was 88.95. The lowest was -46.74. And the median was 4.76.
LUX:ORCHP's Debt-to-EBITDA is ranked worse than 81.48% of 691
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs LUX:ORCHP: 5.20
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Orchid Pharma Debt-to-EBITDA Related Terms
Orchid Pharma Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Orchid Pharma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orchid Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchid Pharma Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orchid Pharma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Orchid Pharma's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Orchid Pharma (LUX:ORCHP) has a Debt-to-EBITDA of 2.61 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Orchid Pharma. This is 45% below median its historical median of 4.76. According to the industry distribution chart, Orchid Pharma ranks #563 out of 691 companies in the Drug Manufacturers industry, placing it in the top 81.5%.
Is Orchid Pharma's Debt-to-EBITDA too high?
Orchid Pharma's current Debt-to-EBITDA of 2.61 is 45% below median its 10-year median of 4.76. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Orchid Pharma's value of 2.61 is 55.4% above this industry median. Based on the distribution chart, Orchid Pharma ranks #563 out of 691 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Orchid Pharma has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Orchid Pharma's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orchid Pharma ranks #563 out of 691 companies for Debt-to-EBITDA. This places Orchid Pharma in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. Orchid Pharma's value of 2.61 is 55.4% above this benchmark. While the company's 10-year median is 4.76 vs. the industry median of 1.68, Orchid Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orchid Pharma's current Debt-to-EBITDA of 2.61 is 55.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Orchid Pharma. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orchid Pharma's current Debt-to-EBITDA is 2.61, which is 45% below median its own 10-year median of 4.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchid Pharma stock overvalued right now?
Orchid Pharma (LUX:ORCHP) has a current Debt-to-EBITDA of 2.61. The stock's GF Value™ is $4.67, compared to a current price of $5.45 — trading 16.7% above its estimated fair value. The current Debt-to-EBITDA is 2.61, which is 45% below median its 10-year median of 4.76 and 55.4% above the Drug Manufacturers industry median of 1.68. Orchid Pharma's overall GF Score™ is 60/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Orchid Pharma (LUX:ORCHP), the current Debt-to-EBITDA is 2.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orchid Pharma (LUX:ORCHP) Overvalued in 2026?
Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued.
The current stock price of $5.45 is trading 16.7% above its estimated GF Value™ of $4.67.
Key valuation signals for LUX:ORCHP:
Debt-to-EBITDA: 2.61 (45% below median its 10-year median of 4.76)
GF Value™: $4.67 vs. price of $5.45 (16.7% above fair value)
Industry Position: 55.4% above the Drug Manufacturers median (#563 of 691)
No single metric tells the full story. See the LUX:ORCHP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
60GF Score
Get the complete analysis for LUX:ORCHP
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:ORCHP has been successfully added to your 
